Opioid use disorder - Articles - Page 2

Research Update

A Rapid Initiation Protocol for Long-Acting Injectable Naltrexone for Opioid Use Disorder

April 1, 2025

Noah Capurso, MD, MHS. Dr. Capurso has no financial relationships with companies related to this material.

Injectable naltrexone can be an effective treatment for opioid use disorder, but it requires complete abstinence before initiation—a process that can take more than a week and cause significant discomfort. Here, researchers evaluate a new protocol designed to accelerate this induction period and improve patient access.

CATR_QA2_Joseph D'Orazio_headshot_sm.png

Expert Q&A

Xylazine and Peripheral Wounds

April 1, 2025

Joseph D’Orazio, MD

Joseph D’Orazio, MD, Associate Professor of Emergency Medicine, Cooper Medical School of Rowan University, Camden, NJ. Dr. D’Orazio has no financial relationships with companies related to this material.

Xylazine is a non-opioid sedative commonly added surreptitiously to illicit opioids. One particularly challenging adverse effect of xylazine exposure is the development of peripheral wounds, some of which can be severe, necessitating surgical intervention and even amputation. In this interview, Dr. D’Orazio teaches us how these wounds might be caused, how to discuss them with your patients, and the best treatment approach.

Fact Sheet

Stimulant Use Disorders Treatment

January 1, 2025

Victoria Hendrick, MD and Daniel Carlat, MD

Dr. Hendrick and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Stimulant use disorders are all too common among patients in psychiatric units.

Fact Sheet

Relapse Prevention Strategies

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Most patients are not able to achieve sobriety from opioids in their first attempt.

Fact Sheet

How to Educate Your Patients About Overdose Prevention

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Drug overdose deaths, the vast majority of which involve opioids, continue to rise in the US.

Fact Sheet

Harm Reduction and Opioid Use Disorder

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Harm reduction refers to a set of strategies aimed at decreasing the negative effects of drug use and other potentially harmful behaviors.

Fact Sheet

Buprenorphine Microinduction

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The standard method of starting a patient on buprenorphine involves having the patient stop all opioids hours to days before the induction.

Fact Sheet

Buprenorphine Monotherapy (Subutex, others)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder (OUD).

Fact Sheet

Buprenorphine Extended-Release Injection Monotherapy (Brixadi, Sublocade)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Extended-release injectable formulations of buprenorphine allow patients to receive doses weekly, monthly, or every eight weeks for patients maintained on a low dose—which improves medication adherence.

Clinical Guidance

Medication Interactions

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Opioid use disorder (OUD) is highly comorbid with medical illness and other psychiatric conditions.